SBRT Delivers Higher Overall Survival Rates Compared to Conventional Radiation Therapy
Abraxane Improves Progression-Free Survival Compared to Decarbazine In Stage IV Disease
Phase III Trial of Avastin and Temozolomide Shows Reduced Risk of Cancer Progression
Abraxane and Gemcitabine Improves Overall Survival
Study Uncovers New Mechanism In Class of Chemotherapy Drugs
Adjuvant Radiation Treatment Shows Improved Survival In Elderly, Early-Stage Patients
Genetic Test Identifies Patients With High Risk of Mortality
Memantine Can Delay Onset Of Cognitive Function Decline
Doxepin Rinse Reduces Pain In Radiation Therapy Patients
Zaltrap Receives Positive Opinion For European Market From CHMP
NCI-Approved CTEP Trials For the Month of November
Trending Stories
- Preparing to take care of each other in ways we never imagined
- 20 years of EGFR research: Ramalingam, Carbone, Politi, Jänne, Govindan reflect
- From the chairs of ECOG-ACRIN: A perspective on indirect costs
- On a new podcast, VCU’s Winn and City of Hope’s Carpten discuss the mission—and the future—of cancer centers
The Cancer Letter’s new podcast offers insight into cancer policy in a landscape of uncertainty - FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers
- What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns”
